Zevra Therapeutics, Inc. · NASDAQ:ZVRA
Zevra Therapeutics — Kempharm — Corporate Update (April 2021)
9 slides from Zevra Therapeutics's corporate update, Apr 8, 2021
Slide 1: Amendment to KP415 License Agreement
K Pharm Amendment to KP415 License Agreement Trademarks referenced herein are held by their respective owners
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended Forward-looking st
Slide 3: Call Participants
Call Participants + Travis Mickle, Ph.D. - President & Chief Executive Officer + R. LaDuane Clifton, CPA - Chief Financial Officer, Secretary & Treasurer
Slide 4: AZSTARYS Approval
ASTARYS™ Approval v On March 2, 2021, the FDA approved AZSTARYS (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, Cll) ANew Once-Daily Treatment for ADHD Consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of d- methylphenidate (d-MPH), co-formulated with immediate-releas
Slide 5: Amendment to License Agreement with Affiliate of GPC
Amendment to License Agreement wi Affiliate of GPC Vv Post-Approval commercial assessments conducted separately and together with the GPC team led to a renegotiation of the economic terms of the KP415 License Agreement Total potential regulatory and sales milestone payments increased to $590M from $
Slide 6: Comparison of Potential Milestones
Comparison of Potential Milestones * Comparing the original and updated commercial forecasts, re-allocated early milestones have the potential to be re-captured quickly and potential for increase in total value wT, Original Amended we ...}©§©§©= eee
Slide 7: Focusing Resources on Commercialization of AZSTARYS
Focusing Resources on Commercialization of AZSTARYS™ « Amended terms allow GPC to re-allocate resources to Corium’s efforts, with the goal to optimize the commercial launch o More resources will be directed into the initial phases of the commercial timeline for AZSTARYS + Based on the approval label
Slide 8: AZSTARYS Commercial Updates from Corium
AZSTARYS™ Commercial Updates from Corium + Led by Perry Sternberg, Corium’s President and CEO, as well as many other executives with prior Shire experience, Corium is building out a best-in-class ADHD sales and support organization + Some payors have indicated initial receptivity to AZSTARYS and the
Slide 9: KemPharm: Operating from a Position of Strength
KemPharm: Operating from a Position of Strength AZSTARYS™ (KP415) - FDAhas approved AZSTARYS NDA - Now eligible to receive up to $590M for regulatory and sales milestone payments - Tiered royalties as percentage of U.S. net sales in the mid-twenties - Corium expected to launch in H2 2021 Partnership